Collect Product
Product Details
Synonyms
HLA-A*0201 & B2M & MAGE-A4 (GVYDGREHTV)
Source
Unconjugated Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Complex Protein (HL4-H82E3) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & GVYDGREHTV peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & GVYDGREHTV).
Predicted N-terminus: Gly 25 & Ile 21
Request for sequenceMolecular Characterization
Unconjugated Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Complex Protein is produced by co-expression of HLA-A*02:01 and B2M loaded with MAGE-A4 peptide.
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™), and it is not biotinylated.
The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 38-43 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE
Unconjugated Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Unconjugated Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Complex Protein (Cat. No. HL4-H82E3) is more than 95% and the molecular weight of this protein is around 45-65 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Unconjugated Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Complex Protein (Cat. No. HL4-H82E3) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-HLA class I Antibody, Human IgG1 (W632) with a linear range of 0.06-1 ng/mL (QC tested).
Protocol
Immobilized Unconjugated Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Complex Protein (Cat. No. HL4-H82E3) at 1 μg/mL (100 μL/well) can bind Anti-HLA-A2&MAGE-A4 Antibody, Human IgG1 with a linear range of 0.06-2 ng/mL (Routinely tested).
Protocol
User Reviews Publish Comment
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Contact Us
Drug Candidate Licensing
